



We are Nitinol.™

An Overview of Superelastic Stent Design

Duerig, Tolomeo

Proceedings of the Int'l Conference on Shape Memory and Superelastic Technologies

SMST-2000

(eds.) S. Russell, A. Pelton

pp. 585-604

2000

AN OVERVIEW OF SUPERELASTIC STENT DESIGN

T. W. Duerig and D. E. Tolomeo

*Cordis Corporation—Nitinol Devices and Components
47533 Westinghouse Drive, Fremont, CA 94539*

ABSTRACT

The purpose of this paper is to contrast the performance of self-expanding and balloon-expandable stents. While both approaches to stenting have proven to be successful in treating a wide range of vascular disease, there are significant differences in philosophy and properties. Many of these differences, such as strength, stiffness (or compliance), recoil, dynamic scaffolding, vessel conformity, and fatigue resistance will be highlighted by studying the mechanics of the stent alone, and then of the stent within a vessel. These differences can be summarized by observing that self-expanding stents provide more anatomically correct scaffolding, while balloon-expandable stents provide rigid and uncompromising reinforcement. Other differences such as corrosion resistance, placement accuracy, and visibility will be briefly summarized as well.

INTRODUCTION

Superelasticity refers to the ability of Nitinol and certain other metals to return to their original shape after severe deformations. As such, it is an extension of the conventional elasticity that all metals exhibit to varying degrees: stainless steel can return to its original length if stretched up to 0.3% of its original length, extremely elastic titanium alloys up to 2%, and superelastic Nitinol more than 10%. While a superelastic material appears macroscopically to be simply very elastic, in fact its mechanism of deformation is quite different from that in conventional elastic materials, where the atomic bonds are simply stretched. When a stress is applied to Nitinol, and after a rather modest elastic deformation, it changes its crystal structure from *austenite* to *martensite*.¹ This stress-assisted phase transition allows the material to change shape as directed by the applied stress. When the stresses are removed, the material reverts to the original austenite and recovers its original shape.

¹ The austenite (parent) crystal structure is cubic in nature; the martensitic (daughter) structure is a complex monoclinic structure.

Nitinol, a nearly equiatomic composition of nickel and titanium, is one of very few alloys that is both superelastic and biocompatible. Moreover, the narrow temperature range within which Nitinol's superelasticity is exhibited includes body temperature. Thus Nitinol has become the material of choice for designers of Self-Expanding (SE) stents. SE stents are manufactured with a diameter larger than that of the target vessel, crimped and restrained in a delivery system, and then elastically released into the target vessel. Performance of SE stents is therefore limited by the ability of the material to store elastic energy while constrained in the delivery system, making Nitinol the ideal choice. While the exact mechanisms of superelasticity in Nitinol are well understood, the application of Nitinol to stents is relatively new [1,2].

The most dramatic and demonstrable attribute of Nitinol stents is their *crush recoverability*. Most if not all Nitinol stents can be crushed fully flat and still elastically recover their original shape without clinically relevant loss of lumen diameter. This attribute is important in superficial indications subject to external crushing such as the carotid artery. Crush recoverability is surely the easiest way one can distinguish Nitinol from stainless steel, but differences between Balloon-Expandable (BE) and SE stents are far more numerous and important.

TERMINOLOGY AND DEFINITION OF FORCES

As a preamble, it is necessary to define some terminology regarding vascular forces and cylindrical shapes in general. Blood vessels experience loads from a variety of sources, such as the pulse pressure of the cardiac cycle, spasms, angioplasty balloons, the placement of a stent, etc. Pressures applied to any cylindrical structure such as a blood vessel result in hoop or circumferential loading of the vessel (Figure 1a).

Both the applied pressure and the resulting hoop stress have units of force per unit area, but differ in direction. *Pressure* refers to the force normal to the vessel wall divided by the surface area of the




Figure 1 The two most common loading modes for stents: (a) radial or hoop, and (b) pinching.

lumen, while *hoop stress* is the circumferential load in the vessel wall divided by the cross-sectional area of the vessel wall (length \times wall thickness). By analogy, water pressure within a pipe results in a tensile hoop stress within the metal pipe itself. The pressure (p) and the hoop stress (σ) in a thin-walled cylindrical object such as a vessel or stent are related by the following equation:

$$\sigma = p \phi / t \quad (1)$$

where ϕ is the vessel diameter and t the vessel wall thickness. We can describe the *hoop force*, F_θ , in a vessel wall in the following manner:

$$F_\theta = \sigma t L = p \phi L / 2 \quad (2)$$

where L is the stent length. In fact, it is more convenient to define *hoop force per unit length*, f_θ , by the next equation:

$$f_\theta = F_\theta / L = \sigma t = p \phi / 2 \quad (3)$$

As an example, a blood pressure of $p = 100$ mm-Hg would apply a hoop force (or hoop load) on an 8mm diameter vessel of 0.053 N/mm:

$$\begin{aligned} f_\theta &= (100 \text{ mm-Hg}) [1.33 \times 10^{-4} (\text{N/mm}^2) / \text{mm-Hg}] (8 \text{ mm}) / 2 \\ &= 0.053 \text{ N/m} \end{aligned} \quad (4)$$

where $1.33 \times 10^{-4} (\text{N/mm}^2) / \text{mm-Hg}$ is the conversion from mm-Hg to N/mm² or MPa. Thus each millimeter of vessel length experiences a tensile load in the hoop direction of 0.053 N.

HOOP OR RADIAL STRENGTH

While hoop stress, total hoop force, and pressure are all equivalent descriptors of vessel forces, we find f_θ to be most convenient because it best correlates to *strength*, or the maximum hoop load that can be carried without failure. In the case of a vessel or pipe, failure is suitably defined as burst or rupture. Failure would occur when the hoop stress exceeds the Ultimate Tensile Strength (UTS) of the material used to manufacture the vessel or pipe.

All the same concepts apply to a stent within a vessel. Pressures acting on the vessel result in hoop loading of the stent that is being used to scaffold, or support, the vessel. The concept of failure, however, now becomes illusive. A stent is intended to hold the vessel open, not to prevent rupture. A stent may fail to perform its intended function and still be fully intact, so the concept of fracture as the failure criteria is no longer relevant. *Failure* is often defined as the onset of permanent, or plastic, deformation (*yielding*). In BE stents there exists some pressure that causes plastic deformation of the stent, thus providing a basis for defining the strength of the stent. (Of course *radial strength* can and is often used instead of hoop strength, with the two quantities related through Equation 3.) In contrast to BE stents, however, Nitinol knows no such limitations: it cannot be deformed or broken due to clinically relevant external stresses. Therefore, Nitinol has no physically appropriate hoop- or radial-strength limit.

RADIAL OR HOOP STIFFNESS

While we cannot compare the strength of a SE stent to a BE stent, we can, and should, compare their stiffness. *Stiffness* measures the elastic response of a device to an applied load and thus will reflect the effectiveness of the stent in resisting diameter loss due to vessel recoil and other mechanical events. Just as with the choice of radial or hoop strength, the choice of radial or hoop stiffness is one only of terminology. However, we prefer the mathematics of hoop stiffness because of its more direct correlation to design. More specifically, we can define the hoop stiffness of a stent or a vessel as the hoop force per unit length required to elastically change its diameter:

$$k_{\theta} = f_{\theta} / \Delta \phi \quad (5)$$

Note that stiffness is the inverse of another commonly used term, *compliance*, or diameter change at a specific applied pressure. Vessel compliance (C_o) is usually reported as the percent diameter change at a given pressure, P_o . Thus hoop stiffness is related to radial compliance through the following equation:

$$k_{\theta} = P_o / 2 C_o \quad (6)$$

With the commonly assumed pressure of $P_o = 100$ mm-Hg (0.0133 N/mm²), we have $k_{\theta} = (0.00665$ N/mm²) / $C_{100 \text{ mm-Hg}}$.

Using analytical mechanics, we can estimate the stiffness of a conventional diamond or z-strut (Figure 2) [3]. While we need not concern ourselves with the detailed calculations, it is interesting to summarize trends. The change in stent diameter due to an applied load is related to the stent geometry as follows:

$$\Delta \phi \propto f_{\theta} n L_s^3 / E w^3 t \quad (7)$$

Alternatively, substituting Equation 3, the change in stent diameter may be related to an applied pressure load by this equation:

$$\Delta \phi \propto p \phi n L_s^3 / E w^3 t \quad (8)$$

where L is the length of a z-strut or half-diamond, w the strut width, t the thickness of the stent, n the number of struts around the circumference, and E is the elastic modulus of the material. It follows from Equations 3 and 8 that the stiffness per unit length, k_{θ} can be determined in the following manner:²

$$k_{\theta} \propto E w^3 t / n L_s^3 \quad (9)$$

The stiffness of a stent does have clinical significance in reducing acute recoil and in determining fatigue life (both discussed below).

² Equations 7–10 are only good approximations for small linear deflections, within the linear elastic range of the material. Larger deformations and more complicated geometry require other techniques such as finite element analysis (FEA).




Figure 2 Most stents are variations on either (a) Zs or (b) diamonds.

PINCHING LOADS AND BUCKLING

Important in Equation 9 is the cubic relationship of hoop or radial stiffness to strut width. If instead a stent is squeezed between two fingers or platens, the stent is subjected to a *pinching load* (Figure 1b). Pinching loads subject struts to out-of-plane bending, i.e., the struts are not bent around the circumference as in radial compression. The dependence deflection of a stent on geometry is rather complex and includes tension, torsion, and bending components, but we can approximate the primary bending component as follows:

$$k_{pinching} \propto E t^3 w / n L_s^3 \quad (10)$$

Note that under a pinching load, strut width now demonstrates only a linear contribution, while thickness a cubic dependence, precisely the opposite of hoop strength, for which strut width has the dominate role. *Thus the stiffness of a stent determined by flattening has little to do with the clinically relevant stiffness of the stent.* In fact, design changes aimed at increasing *crush resistance* may well decrease radial stiffness. Because pinching loads and deflections are far easier to measure than hoop, one must be vigilant not to erroneously use this as a gauge of stent strength or stiffness.

Buckling refers to unstable deformation, meaning that an applied load can be reduced by increasing deformation. Most objects loaded in compression are potentially subject to buckling (e.g., a walking cane if leaned on too hard). Once a structure buckles, its stiffness is generally dramatically reduced. A stent experiencing circumferential compression can, and may in some cases, become unstable and buckle outside the circumferential plane into a half-moon shape. This can be exacerbated if the compression loads are not radially symmetric, as in the *kissing* stent grafts shown in Figure 3. As an out-of-plane deformation, buckling is resisted by the pinching stiffness described in Equation 10. Thus a lower hoop stiffness but more stable shape can be obtained by maximizing thickness and minimizing width. One must be careful to balance the two stiffnesses.

ELASTIC MODULUS AND BIASED STIFFNESS

Next we consider the elastic modulus, E , in Equations 7 to 10, a simple constant for conventional materials, but an enormously complex concept in Nitinol [1]. The modulus of all stainless steel stents is approximately 200 GPa; variations in device stiffness result only from the geometry variations described in Equation 9. Nitinol, however, is a nonlinear, path-dependent and temperature-dependent material, making E anything but a constant. One certainty, however, is that E is always




Figure 3 Two kissing Nitinol stent grafts of equivalent radial stiffness, both shape set to the same circular cross section, but with different pinching stiffnesses; (a) can be crushed in any direction and will return to the desired shape shown; (b) prefers to buckle out of plane and return to a half-moon geometry, occluding one of the branches.

lower in Nitinol than it is in stainless steel. Thus, a stainless steel stent will always be stiffer, or less compliant, than a Nitinol stent made to the same design. In fact, a BE stent will be at least three times as stiff as an identical Nitinol SE stent. Clearly this has important implications to recoil that will be reviewed later in this paper.

The hysteresis or path dependence of Nitinol results in another very important feature termed *biased stiffness*. This concept is illustrated in Figure 4. Shown in light gray is a typical schematic superelastic stress-strain curve for Nitinol, illustrating both nonlinear response and hysteresis. Superimposed on the curve is the crimping and deployment of a self-expanding stent. The axes have been changed from stress-strain to hoop force-stent diameter. This particular schematic stent has been manufactured with an 8 mm diameter (point *a* in Figure 4), crimped into a delivery catheter (point *b*), then packaged, sterilized, and shipped. After insertion to the target site, the stent is released into a vessel, expanding from *b* until movement is stopped by impingement with the vessel (point *c*). Having reached equilibrium with the vessel, recoil pressures are resisted by forces dictated by the loading curve (trace towards point *d*), which is substantially steeper (stiffer) than the unloading line (trace towards point *e*).

In the next section, we will examine this impingement in more detail, but already we can see some of the significance of Nitinol's unusual elastic hysteresis. This biased stiffness means that the continuing opening force of the stent acting on the vessel wall, or *Chronic Outward Force (COF)*, remains very low through large deflections and oversizing. Meanwhile the forces generated by the stent to resist compression, or *Radial Resistive Force (RRF)*, increase rapidly with deflection until a plateau stress is reached. As a matter of definition, we again find it most convenient to define both RRF and COF as hoop forces per unit length of stent, thus allowing a constant value within a family of stents of varying diameter and length. We will discuss the clinical relevance of COF and RRF in later sections, but *in general, stent designers should strive for as high an RRF with as low a COF as possible.*




Figure 4 A typical superelastic stress-strain curve transposed onto a hoop force–diameter diagram, illustrating the concept of biased stiffness; (b) 8 mm stent compressed into a catheter; (c) then released to a diameter; (d) further deformation forces resisted by the radial resistive force, (e) while the opening chronic outward force remains constant and gentle.

Figure 5 shows actual measurements of hoop force versus diameter for a commercially available 10 mm Nitinol stent.³ The device is crimped to 2 mm and is deployed into an emulated 8.5 mm vessel diameter (data at diameters less than 4 mm are not recorded). At 8.5 mm, the RRF is recorded by crimping the stent back to 7.5 mm, and then the stent is unloaded entirely to its original diameter. One can see that the COF is quite constant at 0.035 N/mm throughout the indicated diameter range (8–9 mm). The RRF increases sharply as the stent is deformed from the equilibrium diameter, reaching 0.22 N/mm after a 1 mm deflection. Continued deformation would indicate a plateau at approximately 0.24 N/mm. Note that the RRF is not a property of the stent but must be defined by applying some relevant diameter change, in this case, 1 mm. Note that unloading does not follow the same line as loading but instead shows additional hysteresis, rejoining the original unloading line at the point at which loading began. With cycling, this hysteresis will reduce to nearly zero, and the RRF slope will decrease.

POSTDILATATION AND ACUTE RECOIL

Having described the behavior of a stent alone, we can now examine the impingement and interaction of the stent with the vessel during deployment. To illustrate this, Figure 6 follows the same 10 mm stent illustrated in Figure 5 as it contacts a 7 mm vessel with a hoop stiffness of 0.11 N/mm² (6% compliance at 100 mm-Hg). During this sequence, the vessel will experience tensile hoop

³ The actual diameter of the stent is closer to 10.5 mm. It is typical that self-expanding stents are larger than their nominal diameter. Since the consequence of oversizing is substantially less than the consequence of undersizing a one-sided tolerance is often applied.




Figure 5 Hoop forces measured during release of a commercially available, laser-cut Nitinol SE stent with a nominal 10 mm diameter; release is halted at the center of the intended diameter range of 8 to 9 mm, at which point the stent is compressed to 1 mm in order to demonstrate biased stiffness; after compression, the stent is again unloaded, quickly returning to the original unloading path but with a small hysteresis.

forces, when the stent will be in compression, though for reasons of convenience, they are plotted on the same axis. The stent is released from the delivery catheter and unloads to meet the vessel wall. The stent contacts the vessel at point *a* and reaches an initial equilibrium diameter at point *b*. Note that this equilibrium diameter is dictated by an equilibrium between the compressive stent COF and the tensile hoop forces in the vessel wall. The stent is then balloon dilated to 8.8 mm, forcing stent and vessel to diameter *c*. Finally, the balloon is deflated, allowing the vessel to recoil, achieving a new stress equilibrium at point *d*. During dilation the stent is unloaded, and during recoil it is loaded. Since the stent is now being loaded to the final diameter, equilibrium is now determined by the RRF of the stent rather than the COF. *Except for the biased stiffness of Nitinol, postdilatation of a healthy elastic vessel would be completely ineffective, and return to the original equilibrium diameter at point a.* We should note that there is at least one stainless steel, self-expanding stent on the market, made of braided wire. While stainless steel does not inherently provide biased stiffness, friction between braided wires can emulate this effect.

It is interesting to compare Figure 6 with the same scenario carried out with a balloon-expandable stent (Figure 7). The vessel is the same in Figures 6 and 7 but now it is superimposed with the hoop force versus diameter characteristics of a typical peripheral BE stent. (Note that the sense of the forces for stent and vessel is reversed just as in Figure 6 and that the scale below the axis is much coarser than that above.) In this case, the BE stent is plastically deformed to 8.8 mm by the balloon pressures. Vessel contact is made in passing point *a*, after which both vessel and stent are stretched to point *b*. During deflation, the tensile hoop forces in the stent are relieved until a stress equilibrium with the vessel is achieved at point *c*.

Both BE and SE stents recoil to a diameter less than that of the balloon. Scenarios exist in which the BE and the SE stent exhibit greater recoil, depending upon geometry, vessel compliance, and oversizing. Similarly, the *equilibrium interference stresses resulting from BE and SE stenting are*




Figure 6 Interaction of a vessel with a typical SE stent illustrated by examining the delivery process and postdilatation (note that the stent forces are compressive while the vessel forces are tensile); the stent is released from the delivery system, making vessel contact at point a, then reaching a stress equilibrium at point b; postdilation further unloads the stent and stretches the vessel to point c, and finally deflation of the balloon loads the stent and relaxes the vessel to the final equilibrium at point d.

approximately the same, as is hypotensive risk. The most obvious difference is the enormous difference in balloon pressures used to achieve the final result. While this should cause no damage to a straight vessel, inflation requires stiffer, higher-pressure balloons, and this may increase acute damage to a vessel, particularly in tortuous anatomy in which high-pressure balloons temporarily straighten the vessel, creating trauma at the balloon ends.

DYNAMIC SCAFFOLDING AND CYCLIC EFFECTS

The above analysis shows there are only minor static and acute differences between the BE and SE stents, but now we turn our attention to the postimplant dynamics and chronic outcome. Here we will see large and important differences. We begin by examining responses to vessel diameter changes. Figure 8 will be used to illustrate some important concepts by superimposing the stiffness curves of the BE and SE stents of Figures 6 and 7, with both the original nominal vessel as well as an expanded and a contracted native vessel. These vessel diameter changes can arise from the systolic-diastolic cycle, or from other sources. While somewhat simplistic, this model is a useful way to understand how the intersection points, or equilibrium diameters and stresses, change as the native vessel undergoes change.

On the horizontal axis, one sees that the equilibrium diameter of the SE-stented vessel changes far more than that of the BE-stented vessel. In other words, the BE stent is more effective in preventing diameter change. On the other hand, the Nitinol stent *dynamically scaffolds* or supports the vessel, meaning that if the vessel were to move away from the stent, the stent would follow and continue to apply a force. Support from the BE stent would quickly dissipate and it could, in fact, end up in the vessel lumen. Dynamic scaffolding may play a particularly important role in drug and radiation therapy where the vessel lumen may actually increase over time. While these differences are




Figure 7 Same vessel as shown in Figure 6 now stented with a typical stainless steel, laser-cut stent rated for use up to 9 mm and mounted on a noncompliant balloon; inflation pressures far in excess of those shown in Figure 6 required to bring balloon and stent to 9 mm (b); deflation unloads the stent, then loads it in compression to the final equilibrium (point c) (note that the scale below the axis is much coarser than above).

marked, it is not clear if the better clinical outcome results from rigid or compliant scaffolding. It is, however, clear that the greater diameter change experienced by the Nitinol device creates a complex and severe fatigue environment (discussed later).

Completing the picture, a look at the changes in equilibrium stress indicates that the BE stent experiences larger variations in hoop strength and thus contact pressure, which may contribute to pressure necrosis, or atrophy of the smooth-muscle layer. Thus, while the BE stent reduces the compliance of the vessel, it does so by applying high localized pressures. Because of its over-simplistic approach, Figure 8 understates this effect. Again, however, it is not clear what the clinical relevance of this difference is.

TIME-DEPENDENT EFFECTS

While the cyclic differences between BE and SE stents are significant, the most important differences arise from the time dependency of the vessel-stent equilibrium. The properties of Nitinol itself are not time dependent, but those of tissue are. For short times, vessels can be reasonably modeled as elastic tubes. But over longer time periods, tissue remodeling occurs in response to the




Figure 8 Dynamic effects on the vessel-stent interaction exemplified by considering the effect of variations in the native vessel diameter on the equilibrium forces and equilibrium-stented vessel diameter; light gray curves represent three native vessel diameters (diastolic, midcycle, and systolic, for example); circles illustrate the stented-vessel equilibrium forces and diameters corresponding to BE and SE stents.

interference stresses. BE interference stresses are applied only over a very short distance, and thus stresses are very quickly dissipated without detectable stent migration. A BE stent quickly becomes an inert, stiff prosthesis maintaining a diameter very close to its original diameter. The COF of SE stents, however, acts over a relatively long distance and thus an SE stent migrates towards the outside of a vessel (see the dashed line in Figure 8). Angiographic evidence for migration is commonly observed during follow-ups (Figure 9). While no studies of COF versus migration rate have been published, it would seem logical to believe that migration rates are determined by the *contact pressure of the stent* (the radial force divided by the footprint or contact area of the stent).

Limited data from animals provide some qualitative insights [to be published, D. Wilson, et al.]. There appear to be times when the stent reaches an equilibrium position at the outside of the vessel wall and other times when the outside diameter of the vessel is barreled out. Further there appears to be only a weak dependence of stent growth on oversizing, perhaps indicating a second chronic stress equilibrium is reached once the stent has migrated to the outer layers of the vessel wall. It also appears that the majority of the outward growth occurs during the first 2 weeks of implantation. It is important to note that even this premature evidence is based on healthy animal vessels and not calcified vessels.

Concerns have been expressed about excessive stent oversizing leading to vessel perforation, pressure necrosis, or a stress-related complication, such as Horner's Syndrome. We know of no clinical evidence of this. In fact, animal studies of exaggerated oversizing have demonstrated that the ends of stents can protrude as much as 2 mm outside the adventitia, but remain covered by connective tissue, exhibiting no adverse clinical reaction (Figure 10). Still, it would seem prudent to limit oversizing and reduce COF. Typically, when an SE stent migrates outwards, the lumen does not necessarily follow, but instead hyperplasia occurs and the original lumen diameter is maintained. This contrasts



Figure 9 View of an SE stent 4 months after implantation in an internal carotid artery, illustrating that the stent is scaffolding the vessel from the outside of the vessel wall.

sharply to hyperplasia in BE stents, in which hyperplasia represents true lumen loss. Thus one must be careful in viewing histology slides such as Figure 10: one cannot simply assume that hyperplasia is problematic.

In summary, there are three noteworthy time-dependent differences between BE and SE stents:

- BE stents tend to support from within the lumen, while SE stents support near the outside of the adventitia, embedded deeply into smooth muscle.
- Hyperplasia is not indicative of restenosis or lumen loss in an SE stent as it is in a BE stent.
- SE stents may exhibit chronic lumen opening, while BE-stented lumens can only become constricted with time.

Clearly more research must be done to fully understand the effects of COF and oversizing regimes on stent growth, particularly in diseased vessels. One can envision that perhaps direct stenting will be possible without postdilation, just relying on the COF to gently open the vessel over a period of time. Of course the acute result may not be as aesthetically pleasing as one would obtain with aggressive pre- or postdilation, but certain indications may profit from such gentler treatment. Thus our earlier assumption that one wants to minimize COF and maximize RRF is conservatively based on regulatory considerations and the lack of a proper study and may in fact be incorrect.




Figure 10 Histology slides 6 months after implantation of a 9 mm SE stent in a 5 mm porcine subclavian artery showing that the original lumen is maintained though the stent has migrated well into the vessel wall; view on the right showing two struts at the end of the stent that have migrated outside the vessel itself.

CONFORMABILITY AND WALL APPPOSITION

Conformability refers to the ability of a stent to adopt the tortuous path of a vessel rather than to force the vessel to straighten. Intuitively, one might expect that SE stents conform better to tortuous anatomies. Indeed, many SE stents are very conformable, but there are no technical grounds for this. Conformability depends far more on the design of the stent than on the flexibility of the material from which it is made: segmented, helical, and flexible bridge patterns all tend to provide conformability and can be incorporated equally well into BE and SE designs. Of course the far greater balloon pressures experienced during BE stenting cause an initial straightening and attendant vessel trauma. But after deflation a well-designed BE stent should relax to the vessel morphology.

Wall apposition refers to the ability of a stent to remain in close contact with the wall of the vessel. Separation from the wall can occur if the vessel cross section is eccentric, when the vessel changes diameter along its length, or at a bifurcation. A BE stent takes on a rigid cylindrical character during balloon expansion and is quite forceful in dictating a circular vessel cross section—thus the acute appearance is typically perfect, with good apposition and an excellent lumen. An SE stent, on the other hand, will tend to conform to the native cross section and axial shape and to fill the available lumen without forcing acute change—the result is often not as aesthetically pleasing but less invasive. Moreover, if the vessel morphology changes due to remodeling, flexing, or crushing, an SE stent will move to fill the changing lumen, while the BE stent remains static.

While the self-expanding process is generally gentler and physiologically more correct, we need to be careful not to assume that all SE stents are the same in this regard. Designs with a low pinching stiffness will tend to conform better than very stiff designs (though as mentioned earlier, buckling can occur if one goes too far). As an extreme example, Figure 11 shows two commercially available self-expanding stents of the same diameter deployed into flattened lumens. Note that the same results are obtained if one deploys the stents into a circular cross section and then flattens them: thus apposition is both a static and dynamic design consideration. The stent on the left has a higher pinching stiffness and a lower radial stiffness than does the stent on the right, and thus is very insistent in maintaining a circular cross section.




Figure 11 Two commercially available SE stents of the same nominal diameter deployed into a flattened lumen; stent on the right exhibits excellent wall apposition, while the one on the left does not.

PULSATILE FATIGUE

Native vessels undergo diameter changes of approximately 3 to 10% when subjected to a 100 mm-Hg pulse pressures [4]. A stent placed in these environments is usually expected to remain patent for 10 years, or 40 billion systolic cycles. This is no easy task, and again BE and SE stent design philosophies are in juxtaposition. Stainless steel stents cannot survive such large diameter changes but are sufficiently rigid to prevent the vessel from *breathing* due to the pulse pressure. Vessels stented with BE stents generally pulse less than 0.25% of their diameter, making fatigue essentially a stress-controlled problem. As shown in Figure 8, Nitinol stents are generally similar in compliance to a healthy vessel, and thus undergo much larger pulsatile diameter changes (albeit somewhat reduced from those of the native vessel).⁴ Fortunately, the displacement-controlled fatigue lifetime of Nitinol far exceeds that of ordinary metals, and stents are able to survive this harsh service.

The FDA currently requires that a statistically relevant number of stents are tested to 400 million cycles under clinically relevant conditions and that no failures are observed. It is rather parochial to think that one can understand and predict life without causing failure. Ideally, one should test to failure and project a safety margin with respect to an endurance limit. This can be done theoretically by using a strain-based Goodman approach, approximating survival by considering a *pulsatile strain*, $\Delta\epsilon$ (cyclic pulse amplitude due to pulse pressure) and a *mean strain*, ϵ_m (the strain at mid-pulse). Assumptions regarding pulse pressure (Δp) and the stented vessel compliance yield a value for $\Delta\epsilon$, the principle driver for fatigue damage. Mean strains in SE stents can be estimated from assumptions concerning equilibrium diameters, vessel compliance, tortuosity, and oversizing. Such approaches are also used to evaluate the life of BE stents, but there are no substantial oversizing strains in BE stents. Instead, mean strains arise from residual strains from the plastic deformation.

⁴ Obviously it is possible to design an SE stent that is as stiff as a BE stent in order that fatigue can be ignored. It is our assumption here that a high compliance is desirable feature of an SE stent.

Analyses such as these are complex and beyond the scope of this paper. Intensive work is underway to better understand the effects of mean strain on fatigue lifetime [5–8]. All studies indicate that the lifetime of Nitinol at high mean strains is far better than one would expect using classical Goodman analysis techniques. This is particularly important in tortuous anatomies, since static bending tends to increase mean strains but have little effect on pulsatile strain. In the end, we cannot say that the pulsatile life of Nitinol stents is better or worse than BE stents, just that their diametrically opposed approaches may suit individual indications in different ways.

BENDING/CRUSHING FATIGUE

Often ignored are a host of other fatigue influences, including crushing and bending as one might experience under the inguinal ligament or in the popliteal, as well as tensile and bending fatigue one might experience in the coronary vessels as a result of the systolic expansion of the heart. Particularly challenging is the first, anatomy that severely flexes and/or buckles a very large number of times and that cannot practically be prevented from doing so by reinforcement with a stiff BE stent. Nitinol performs far better than any other known metal in displacement-controlled environments such as these. But even so, such severe dynamic cycling may exceed even the limitations of existing Nitinol stents. The second type of fatigue condition also warrants some discussion. As the heart expands and contracts, the topology of the surface undergoes large changes exposing vessels to both high-cycle bending and stretching. First generation BE stents were very rigid and would locally reinforce to the extent that bending and stretching fatigue was not an issue. However, the market is demanding stents that are increasingly flexible. And even though the current BE devices are radially stiff, they are typically very compliant in bending and tension and are thus subject to these fatigue modes. Ultimately this may lead to advantages for the more fatigue-resistant Nitinol.

THERMAL RESPONSE AND A_f CONTROL

The origins of superelasticity were briefly outlined in the introduction of this paper. While a complete mechanistic description is unnecessary to the task at hand, it is important to note that the transformation between austenite and martensite is driven by temperature as well as by stress. When no stress is applied, we define A_f to be the temperature at which martensite is completely transformed to austenite upon heating.⁵ Within a limited range, alloy producers can control the A_f temperatures of Nitinol. The higher the A_f temperature, the lower the stress needed to induce the transformation to martensite. Thus the difference between body temperature and the A_f temperature dictates the properties of the material and thus the apparent stiffness of the stent. For each degree that A_f is below body temperature, the tensile loading and unloading stresses of Nitinol increase by approximately 4 N/mm. These are very important concepts that can be vividly demonstrated simply by feeling a Nitinol stent at room temperature and body temperature. Figure 12 illustrates the temperature dependence by comparing the unloading-loading-unloading cycle for a 10 mm Nitinol stent at three different temperatures.

Choosing and controlling the A_f temperature of a stent is one of the most important tasks facing design engineers. A_f must be below body temperature to assure the stent will fully deploy. The lower A_f is set, the stiffer the stent; but a very low A_f can lead to unacceptably high COF values. Of course, a designer can compensate for a low A_f by designing a weaker structure (e.g., reducing strut width). This, though, will severely reduce RRF. In fact, the most efficient combination of RRF and

⁵ This is a somewhat simplified definition that ignores several complexities that are important but have no bearing on this specific subject.




Figure 12 Commercially available 10 mm stent unloaded in the same cycle as shown in Figure 5, but at three different temperatures (note that COF increases by nearly 50% as the stent is warmed from 30 to 37°C).

COF is obtained by using A_f temperatures as close to body temperature as possible (without running the risk of being above body temperature, of course).

Still another important consideration illustrated in Figure 13 relates to elevated temperature exposure during shipping, storage, or sterilization. As ambient temperature is increased, the forces applied by the stent on the delivery system increase. If the temperature becomes too great, either the stent will damage the delivery system or the stent will damage itself and fail to recover fully to its prescribed diameter once released [9]. It is necessary, therefore, to control both the stent A_f and the temperatures to which it may be exposed after crimping. Some manufacturers have put thermal markers on packaging to assure that the stent system is not exposed to temperatures above tested limits.

DEPLOYMENT PRECISION AND FORESHORTENING

Obviously stent performance is critically dependent upon getting the stent to the target location and, once there, accurately deploying it. There are a variety of factors that contribute to accuracy.

Foreshortening refers to the fact that the opening of the geometry of Figure 1 results in geometric shortening. If there is uncertainty in the direction of the foreshortening, this can lead to large inaccuracies in deployment. In fact there are a variety of ways to reduce this effect. One can design stents such that strut shortening is compensated by stretching of bridges (see Figure 1). Other designs exist using wave designs such that diamonds or struts initially lengthen during expansion, then shorten. Foreshortening can be somewhat more easily eliminated in BE-stent design, but is clearly a design, not a material, issue.

- As the leading end of the stent begins to emerge from the constraint, there is a natural tendency for it to spring forward. In the extreme, the stent can jump completely out of the delivery catheter. Several attributes influence this tendency, including bridge design, longitudinal stiffness, pinching stiffness, and friction. While it can be managed to a minimum in an SE stent, this potential source of inaccuracy simply does not exist in a BE stent.
- Finally, most SE delivery systems consist of an inner and an outer member, which are axially stressed during delivery. Since designers strive towards flexibility in delivery catheters, these members are generally not rigid and thus they stretch or compress. Deployment by experienced clinicians and the application of some prestress to the delivery system will mitigate these effects, but again this is an issue that is peculiar to SE stents.

In summary, while the accuracy of SE stenting has improved dramatically, and will likely continue to improve, it would appear that BE stents will continue to be more accurate.

X-RAY AND MR VISIBILITY

The x-ray density of Nitinol is very similar to stainless steel (see Figure 13). Differences in perceived opacity are a result of stent design as well as the resolution and energy of the imaging equipment. As stents continue to evolve towards lower mass and finer features, imaging equipment will have to improve. Some stent manufacturers have resorted to coatings or markers to improve visibility. This is not a straightforward solution: as will be discussed below, dissimilar metal contact can dramatically impact the corrosion resistance of Nitinol. Gold and platinum in particular are ill-advised materials.




Figure 13 Two geometrically identical stents viewed radiographically.

MR visibility, however, is quite different between stainless steel and Nitinol. Stainless steel interacts strongly with the MR field and can create artifacts, making imaging of nearby areas difficult. With appropriate surface treatment, Nitinol exhibits a very low magnetic susceptibility and provides clean detailed images. Interestingly, Nitinol is not universally MR compatible due to differences in surface treatment and design (see Figure 14). Certain common surface conditions can be magnetic and can interfere with imaging.




Figure 14 Two different commercially available Nitinol SE stents shown by MR imaging, illustrating the importance of surface finish and design on MR compatibility.

THROMBOGENICITY AND BIOCOMPATIBILITY

These attributes have been discussed in detail in other publications [10,11]. In short, both thrombogenicity and corrosion resistance of properly treated Nitinol are superior to stainless steel, but it appears unlikely that these differences are of clinical significance—or at least no viable evidence of this sort has been presented. Still, a few questions are often asked and should be summarized.

- There is often concern expressed regarding nickel allergies and the 50 at.% Ni content of Nitinol. Although stainless steel contains less nickel, the nickel is released at a more rapid rate than in properly treated Nitinol. The reasons for this relate to the extremely high-energy bonds formed between nickel and titanium and the chemistry of the surface. The surface of properly treated Nitinol is the same, very stable TiO_2 that is formed on pure titanium [12].
- Dissimilar metal contact has already been mentioned. Theoretically, whenever two dissimilar metals are in contact, there is a galvanic couple causing one of the two metals to corrode at an accelerated rate and the other at a retarded rate. The galvanic potential of stainless steel and Nitinol are very similar, making this effect almost unmeasurable. Tantalum and Elgiloy too are galvanically similar to Nitinol and have been shown to be safe. This does not mean, however, that there is never an issue. Contact with noble metals, such as gold or platinum, should be avoided unless the coated areas are completely protected from the corrosive media. Stainless steel corrosion performance can also be dramatically deteriorated by contact with gold.
- Concerns have been expressed about scratches. The concern revolves around the fact that both stainless steel and Nitinol resist corrosion through the formation of a passive oxide layer that

seals and protects the reactive metal from the corrosive media. When damaged, these passive layers reform and reprotect the base material. The concern is whether the layer can heal itself if no oxygen is present or if the device is immersed in a corrosive environment when damaged. In short, there does not appear to be a significant difference between stainless steel and Nitinol stents. In general, however, any fretting opportunities should be avoided whenever possible, regardless of the stent material: this includes braided wire stents and designs that incorporate interlocking features.

Finally, various Nitinol stent manufacturers produce different surface finishes, ranging from dark blue oxides to highly polished and bright surfaces. Most recent work indicates that highly polished surfaces with no coloration are preferable [13].

MARTENSITIC NITINOL

While the vast majority of Nitinol stents are superelastic and self-expanding, three other types of Nitinol stents have been proposed: stents that are installed cold, then thermally recover their specified shape when exposed to body temperature [14]; stents that recover their desired diameter by heating above body temperature after insertion into the body [15]; and BE martensitic stents that can be later heated to cause shrinkage to assist in removal [16]. The last of these is probably the most interesting, but has still not been commercially successful. In addition to removability, these stents offer more uniform expansion, but at a price: martensitic Nitinol is inherently weak and requires large, bulky structures. Moreover, martensitic Nitinol is not superelastic and thus offers none of the typical advantages of Nitinol SE stents.

CONCLUSIONS

SE and BE stents differ in many respects, but thematically summarizing, SE stents become part of the anatomy and act in harmony with native vessels while BE stents change the geometry and properties of the anatomy. SE stents assist while BE stents dictate. Clearly, there is a place for both in radiology suites. Perhaps the most important unknown regarding SE stenting concerns the effect of the COF, or Chronic Outward Force, of a stent. Physicians are beginning to experiment with eliminating postdilation and relying on chronic outward force to slowly remodel the vessel to the desired diameter. While acute results may not be as good, the lessened trauma may lead to a better chronic outcome.

REFERENCES

1. T. W. Duerig, K. N. Melton, and C. M. Wayman, in *Engineering Aspects of Shape Memory Alloys* (Boston: Butterworth-Heinemann, 1990).
2. K. W. Lau and U. Sigwart, in *Indian Heart J.* **43**, no. 3 (1991), 127.
3. D. E. Tolomeo and T. W. Duerig, *Criteria for Fatigue Resistant Design of Superelastic Stents* (forthcoming).
4. O. M. Pederson, A. Aslaksen, and H. Vik-Mo, in *Journal of Vascular Surgery* (1993), 596–601.
5. B. Berg, ICOMAT-99, Barolucia, Argentina (forthcoming).
6. M. Santinoranont, S. Davidson, and D. E. Tolomeo, in *SMST-2000: Proceedings of the International Conference on Shape Memory and Superelastic Technologies*, eds. S.M. Russell and A.R. Pelton, (Pacific Grove, California: International Organization on SMST, 2001).

7. K. Perry and C. Kugler, in *SMST-2000: Proceedings of the International Conference on Shape Memory and Superelastic Technologies*, eds. S.M. Russell and A.R. Pelton, (Pacific Grove, California: International Organization on SMST, 2001).
8. W. Harrison and Z. Lin, in *SMST-2000: Proceedings of the International Conference on Shape Memory and Superelastic Technologies*, eds. S.M. Russell and A.R. Pelton, (Pacific Grove, California: International Organization on SMST, 2001).
9. V. Martynov and F. Basin, in *SMST-2000: Proceedings of the International Conference on Shape Memory and Superelastic Technologies*, eds. S.M. Russell and A.R. Pelton, (Pacific Grove, California: International Organization on SMST, 2001).
10. R. Venugopalan and C. Trepanier, in *SMST-2000: Proceedings of the International Conference on Shape Memory and Superelastic Technologies*, eds. S.M. Russell and A.R. Pelton, (Pacific Grove, California: International Organization on SMST, 2001).
11. B. Thierry, et al., in *SMST-2000: Proceedings of the International Conference on Shape Memory and Superelastic Technologies*, eds. S.M. Russell and A.R. Pelton, (Pacific Grove, California: International Organization on SMST, 2001).
12. C. M. Chan, S. Trigwell, and T. Duerig, in *Surf. and Interface Anal.* **15** (1990), 349.
13. C. Trepanier, et al., in *J. Biomed. Material Res.* **43** (1998), 433–440.
14. A. Balko, et al., in *J. Surgical Research* **40** (1986), 305.
15. R. J. Alfidi and W. B. Cross, U.S. Patent 3,868,956 (1975).
16. R. L. Hess, U.S. Patent 5,197,978 (1993).